{
  "docId": "019de075-37cf-77a8-ac06-803553b19741",
  "docSlug": "fb1f3d8675ea71173cb7fbde0c578736",
  "documentTitle": "Sarissa Capital | Activist Presentation Deck | 36 slides",
  "authorId": "sarissa-capital",
  "authorName": "Sarissa Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 29,
  "pageCount": 36,
  "prevPage": 28,
  "nextPage": 30,
  "slideType": "nominee_bio",
  "function": "introduce_nominees",
  "density": "balanced",
  "nDataPoints": 1,
  "notes": "Uses a press release excerpt to expose a contradiction between the director's stated qualifications and the company's current strategic needs.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-37cf-77a8-ac06-803553b19741/29",
  "deckHref": "/decks/019de075-37cf-77a8-ac06-803553b19741",
  "deckJsonHref": "/decks/019de075-37cf-77a8-ac06-803553b19741.json",
  "deckAnchorHref": "/decks/019de075-37cf-77a8-ac06-803553b19741#slide-29",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.86,
        "x": 0.07,
        "y": 0.74
      },
      "kind": "callout",
      "text": "The value of 18 years of experience in oncology-focused drug development (to use Alkermes’ words) is now irrelevant except perhaps with the oncology spin",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e1ae647e-07ae-4028-a01b-68db4c3b8230",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.76,
        "x": 0.07,
        "y": 0.46
      },
      "kind": "other",
      "text": "DUBLIN, Sept. 13, 2019 /PRNewswire/ Dr. Gaynor, who currently serves as the President of Research & Development at Neon Therapeutics, brings 18 years of experience in oncology-focused industrial drug development in addition to a distinguished career in academic medicine. He is board-certified in internal medicine and medical oncology and hematology.",
      "attrs": null,
      "subkind": "unclassified",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0ea18464-e4a6-4285-959b-9bd377aa7660",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.57,
        "x": 0.07,
        "y": 0.26
      },
      "kind": "other",
      "text": "Alkermes Announces the Appointment of Richard Gaynor, M.D. and Andy Wilson to its Board of Directors and the Retirement of Director Floyd Bloom, M.D.",
      "attrs": null,
      "subkind": "unclassified",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "54feb7d7-0517-4091-8ee0-588667bb2104",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.86,
        "x": 0.07,
        "y": 0.12
      },
      "kind": "paragraph",
      "text": "a cancer specialist is no longer needed on the board as Alkermes refocuses on neuroscience",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "39e95135-cbea-473f-8787-dc7a38e6e9aa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.2,
        "x": 0.03,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "Source: Alkermes Press Release (9/13/2019)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1ec9c41f-8510-4bca-8f78-5a9d4abc8679",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.62,
        "x": 0.07,
        "y": 0.05
      },
      "kind": "title",
      "text": "DO NOT RE-ELECT RICHARD GAYNOR",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ba82975d-13a7-4388-9bdf-3b4b5746b22d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Anadiplosis",
      "slug": "anadiplosis",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "d2027247-276c-4934-ac03-8cffb44cfba2",
      "evidence": "The value of 18 years of experience in oncology-focused drug development (to use Alkermes’ words) is now irrelevant except perhaps with the oncology spin",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "expose_contradiction",
      "slug": null,
      "matchId": "9469444a-2e8e-46c3-9e2f-f1b94039db14",
      "evidence": "Contrasts the director's oncology background with the company's new neuroscience focus to argue for removal.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 30,
      "from": 26,
      "beatId": "a9eecc6c-b32d-4c79-9394-018666391025",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "The Call",
      "beatSlug": "overcoming-monster-the-call",
      "evidence": "Slides 26-30 present the call to action for shareholders to vote for Sarissa's board nominees",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}